Leerink Partners Resumes Neurocrine Bio. (NBIX) at Outperform on NBI-98854 and Elagolix Blockbuster Potential
Tweet Send to a Friend
Leerink Partners resumes coverage on Neurocrine Bio. (NASDAQ: NBIX) with a Outperform rating and a price target of $67.00, saying ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
